Compare fisetin, quercetin alone, and prescription dasatinib-plus-quercetin without confusing animal findings or small disease-specific trials with proven human life extension.
Neither fisetin nor quercetin is established as a supplement that extends human lifespan. Fisetin has notable preclinical senotherapeutic research; quercetin appears in early human studies combined with the prescription drug dasatinib. Those are different interventions with different evidence.
Senolytics aim to remove certain senescent cells rather than merely changing inflammatory signaling. Senescence can also play roles in repair, so indiscriminately treating every senescent cell as harmful oversimplifies the biology.
Activity in a cell culture or mouse model does not establish a safe, effective schedule in a healthy person.
The 2018 EBioMedicine fisetin paper30373-6.pdf) reported senotherapeutic effects and health/lifespan findings in preclinical models. This is not a human longevity trial.
Commercial fisetin labels and online high-dose “burst” protocols therefore should not be described as validated life-extension prescriptions. Optimal human dose, schedule, and meaningful long-term outcomes remain uncertain.
The 2019 preliminary human study30591-2/fulltext) examined dasatinib plus quercetin in people with diabetic kidney disease and reported changes in senescent-cell measures.
It was not a large mortality trial, did not study routine prevention in healthy adults, and does not demonstrate that quercetin alone produces the same outcome. Dasatinib is a prescription oncology drug with meaningful risks, not an ingredient to add to a self-directed supplement stack.
Fisetin and quercetin products can differ in delivery systems and active content. A phytosome or other absorption-enhancing claim needs formulation-specific evidence. Higher exposure does not automatically mean better senolysis or greater safety.
Check the active ingredient amount and independent quality documentation, but recognize what those checks cannot answer: whether the intervention improves your long-term health.
For wider context, read our senolytics overview and the NMN evidence guide, another example of why a plausible mechanism should not become a lifespan promise.
Discuss use with a clinician if you take medications, have kidney or liver disease, or are undergoing cancer treatment. Avoid combining several experimental “anti-aging” agents at once; it becomes harder to identify side effects and interactions.
We do not recommend a DIY dasatinib regimen or an unvalidated high-dose fisetin schedule. Clinical-trial eligibility is a more appropriate route for investigating an experimental treatment.
Which is stronger? There is no simple clinically validated ranking for healthy humans. Different models, tissues, and preparations can produce different results.
Can I take both? A proposed complementary mechanism does not prove that a combination is effective or safe for you.
Does better absorption settle the choice? No. Pharmacokinetics and clinical outcomes are different evidence questions.
Should I buy a senolytic supplement after 60? First review practical supplement choices over 60 and prioritize established needs rather than assuming age alone is an indication.
The science is worth following, but fisetin, quercetin alone, and D+Q must remain separate in the comparison. Do not transfer disease-specific or animal results into promises about a healthy person's lifespan.